



EIA for Quantitative Determination of anti-FGFR3-Antibodies

Introduction

Fibroblast growth factor receptor 3 (CD333) is a protein that in humans is encoded by the FGFR3 gene. Fibroblast growth factor receptor 3 interact with FGF8 and FGF9. FGFR3 inhibitors are in early clinical trials as a cancer treatment for urothelial carcinoma.

FGFR3 antibodies have been reported in sensory neuropathy.

The CellTrend anti-FGFR3-antibody-EIA is designed for the determination of Antibodies (IgG) against the FGFR3 in serum.

Principle of the test

The CellTrend anti-FGFR3-antibody-EIA is an antibody screening test. The FGFR3 protein has been pre-coated onto a microtiter plate. During the first incubation the anti-FGFR3-antibodies of the samples are immobilised on the plate. The auto-antibodies are detected with a POD labeled anti-human IgG antibody. In the following enzymatic substrate reaction the intensity of the colour correlates with the concentration and/ or avidity of anti-FGFR3-antibodies.

Performance Characteristics

Standard curve:

6 standards between 1.25 U/ml and 40 U/ml

Healthy controls:

Mean: 8.7 Units

SEM: 0.8 Units/ml

Sample materials:

Serum, Plasma


Intraassay-Precision (n=10):

Sample 1 (18.2 U/ml): 6.6%

Interassay-Precision (n=10):

Sample 1 (23.0 U/ml): 14.05%

Typical Standard Curve



Assay Procedure

Incubation of samples/ standards/ controls	100 µl	120 min, 4°C
Wash		
Incubation of detection antibody	100 µl	60 min, room temperature
Wash		
Substrate incubation	100 µl/well	20 min, room temperature
Add Stopp solution	100 µl/well	
Read at 450nm		

Order information

Product	Bestell-Nummer	Preis (€)
EIA Quantitative Determination of anti-FGFR3-Antibodies, 1x96 Best.	16100	950,-